Business context and reporting period
Prestige Brands Holdings, Inc. (the registrant named in the filing) markets and distributes OTC healthcare and household-cleaning products. This Form 10-Q covers the quarter and six months ended September 30, 2013, the second quarter and first half of fiscal 2014. The filing is not identified as a Prestige Consumer Healthcare Inc. filing; verify the issuer identity.
Financial performance and position
| Metric | Three months ended September 30, 2013 | Six months ended September 30, 2013 |
|---|---|---|
| Total revenue | $168.4 million; up 4.1% year over year | $311.4 million; up 0.8% |
| Gross profit / margin | $94.7 million / 56.2% (prior year 55.9%) | $178.2 million / 57.2% (prior year 56.4%) |
| Operating income / margin | $53.8 million / 31.9% | $103.2 million / 33.1% |
| Net income / diluted EPS | $32.8 million / $0.63 | $53.5 million / $1.03 |
For the six-month period, operating cash flow was $55.6 million, versus $60.4 million a year earlier. Capital expenditures were $2.3 million, implying operating cash flow less capital expenditures of approximately $53.3 million. Cash increased to $26.8 million from $15.7 million at March 31, 2013; current assets were $182.7 million and current liabilities $89.1 million.
At September 30, 2013, debt principal was $985.0 million, compared with $978.0 million at March 31; debt net of discount was $978.7 million. Cash less debt principal was approximately negative $958.2 million. The $95 million ABL revolver was drawn by $47.5 million, leaving $47.5 million of stated capacity. The company reported compliance with debt covenants. Variable-rate debt totaled $485.0 million.
Changes versus the prior comparable period
- Quarterly revenue growth reflected the Care acquisition and analgesic product launches, partly offset by the Phazyme divestiture and competitors’ recalled products returning to market. Six-month revenue growth was modest.
- Gross margin improved in both periods, which management attributed mainly to lower promotional spending, sourcing savings and product mix. Quarterly advertising and promotion expense rose to $26.0 million from $23.5 million, supporting launches; OTC contribution margin declined slightly.
- Operating income rose to $103.2 million for six months from $95.0 million. Lower G&A—partly reflecting prior-year GSK transition/integration and other costs—and lower interest expense contributed to the improvement.
- Net income increased substantially, but comparability is affected by a one-time $9.1 million tax benefit from a state tax-law change. The six-month effective tax rate was 24.5%, versus 38.9% a year earlier.
- Operating cash flow fell despite higher net income, primarily reflecting working-capital movements and lower noncash tax charges. Investing cash use increased to $57.5 million, largely from the Care acquisition.
Outlook, commentary, risks and unusual items
- Management estimated a 36.2% effective tax rate for the remaining quarters of fiscal 2014, down from its prior 38.3% estimate, mainly due to lower state and Australian taxes. The filing provides no clear full-year revenue or earnings guidance.
- Management expected depreciation and amortization to increase in the second half because of implementation of a new ERP system. It cautioned that implementation could cause transaction errors, processing inefficiencies or business disruption.
- Care Pharmaceuticals was acquired July 1, 2013, funded with cash and senior secured borrowings. Preliminary net assets acquired were $56.8 million, including $23.1 million goodwill and $31.5 million intangible assets; management said the pro forma effect on revenue and earnings was not material.
- Interest expense declined, reflecting lower average debt and borrowing rates after the February 2013 term-loan refinancing. A one-percentage-point increase in rates on variable-rate debt was estimated to reduce pretax earnings and cash flow by approximately $2.4 million for the quarter and $5.8 million for six months.
- Key risks include customer concentration (Walmart represented 19.2% of quarterly and 20.4% of six-month gross sales), competition and private-label products, reliance on third-party manufacturers, distribution-center disruption, commodity and transportation costs, international and currency exposure, and high leverage. Goodwill and intangible assets totaled approximately $1.59 billion; no impairment was recorded for the six months.
- Routine legal claims were disclosed; management did not expect their resolution, net of reserves, to materially adversely affect the company. The company reported no off-balance-sheet arrangements and no outstanding derivatives.
Important facts for investors to verify
- Confirm the issuer and filing identity: the supplied filing is for Prestige Brands Holdings, Inc., despite the request metadata naming Prestige Consumer Healthcare Inc.
- Assess how much reported earnings growth depends on the $9.1 million one-time tax benefit and whether subsequent tax rates align with management’s 36.2% estimate.
- Track organic sales, promotional investment and competitive pressure in gastrointestinal and cough-and-cold products, separating Care acquisition effects from underlying growth.
- Monitor debt, revolver availability, covenant headroom, refinancing needs and exposure to variable interest rates.
- Review Care integration and the final purchase-price allocation, as the acquisition accounting was preliminary, alongside ERP implementation and potential brand-impairment indicators.